HBW Insight speaks to Bayer Consumer Health's head of R&D and chief scientific officer David Evendon-Challis about the opportunity presented by a new generation of OTC digital therapeutics as well as by AI-driven self-care. Defined by the Digital Therapeutics Alliance as “delivering evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease,” the digital therapeutics sector saw tremendous growth and investor interest during the pandemic.

AI has huge potential as a foundational technology, to be applied across the whole product development life cycle.
Bayer Consumer Health’s head of R&D and chief scientific officer David Evendon-Challis

Related resources

JUN 22, 2023

‘Faster, Better, More Efficient’ – Why Bayer Is Investing in ‘Precision Health’

Like other big global OTC players, Bayer Consumer Health is stepping up its investment in digital self-care.

Biopharma professional on laptop browsing Pink Sheet for global policy and regulatory insights.
MAY 01, 2022
Regulatory & Compliance

Your Keys to Understanding EU Transparency

A collection of Pink Sheet articles covering evolving EU regulations on clinical trial disclosure and transparency